# Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-osimertinib-as-first-line-treatment-and-sequential-therapy/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hongfu Cai,Longfeng Zhang,Na Li,Shen Chen,Bin Zheng,Jing Yang,Lizhu Weng,Mao-Bai Liu |
| Citations | 51 |
| DOI | 10.1016/j.clinthera.2018.12.007 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2909200466 |
| PMID | 30639208 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Longfeng Zhang](https://scholariq.org/researchers/longfeng-zhang/)

## Paper journal

- [Clinical Therapeutics](https://scholariq.org/journals/clinical-therapeutics/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.